About this trial
Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.
Eligibility criteria
Qualifiers
Voluntarily participate in this study and sign the informed consent form;
Age 18-70 years old;
Primary debulking surgery for epithelial ovarian cancer (including neoadjuvant chemotherapy), with or without abdominal and distant metastasis (≥ IIB stage);
Colonoscopy negative (no mucosal layer invasion);
Disqualifiers
Has a history of other malignant tumors or is undergoing other anti-tumor treatments;
Has severe underlying medical conditions that make surgery intolerable;
Epithelial ovarian cancer diagnosed incidentally during emergency surgery;
Participates in other clinical studies simultaneously;
Trial design
Treatments tested in this trial
- Rectosigmoid Lesion Excision +tumor cell debulking surgery
- Rectosigmoid Resection +tumor cell debulking surgery
Treatment groups
Sponsors and collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
Tongji Hospital
Collaborator
Zhejiang University
Collaborator
Zhejiang Provincial People's Hospital
Collaborator
Zhejiang Cancer Hospital
Collaborator
Huzhou Central Hospital
Collaborator
Ningbo Women & Children's Hospital
Collaborator
Shaoxing People's Hospital
Collaborator
The Central Hospital of Lishui City
Collaborator
Women's Hospital School Of Medicine Zhejiang University
Collaborator